BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466. [PMID: 7739682 DOI: 10.1056/nejm199506013322202] [Cited by in Crossref: 831] [Cited by in F6Publishing: 177] [Article Influence: 30.8] [Reference Citation Analysis]
Number Citing Articles
1 Booth JC, O'Grady J, Neuberger J;  Thr Royal College of Physicians of London and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut. 2001;49 Suppl 1:I1-21. [PMID: 11413125 DOI: 10.1136/gut.49.suppl_1.i1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
2 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 32.7] [Reference Citation Analysis]
3 Wang XH, Netski DM, Astemborski J, Mehta SH, Torbenson MS, Thomas DL, Ray SC. Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution. J Virol 2007;81:6513-22. [PMID: 17329332 DOI: 10.1128/JVI.02276-06] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
4 Huynh T, Hu KQ. Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma. Front Med 2019;13:658-66. [PMID: 31655955 DOI: 10.1007/s11684-019-0707-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. [PMID: 16614742 DOI: 10.7150/ijms.3.47] [Cited by in Crossref: 454] [Cited by in F6Publishing: 431] [Article Influence: 28.4] [Reference Citation Analysis]
6 Zhubi B, Mekaj Y, Baruti Z, Bunjaku I, Belegu M. Transfusion-transmitted infections in haemophilia patients. Bosn J Basic Med Sci 2009;9:271-7. [PMID: 20001991 DOI: 10.17305/bjbms.2009.2777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
7 Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46:536-544. [PMID: 21132575 DOI: 10.1007/s00535-010-0349-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
8 Jia W, Weng J, Fang C, Li Y. A dynamic model and some strategies on how to prevent and control hepatitis c in mainland China. BMC Infect Dis 2019;19:724. [PMID: 31420017 DOI: 10.1186/s12879-019-4311-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Helal SF, Gomaa HE, Thabet EH, Younan MA, Helmy NA. Impact of IL-10 (-1082) promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol 2014;7:19-24. [PMID: 24833945 DOI: 10.4137/CGast.S13658] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
10 Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999;73:2938-46. [PMID: 10074143 DOI: 10.1128/JVI.73.4.2938-2946.1999] [Cited by in Crossref: 142] [Cited by in F6Publishing: 71] [Article Influence: 6.2] [Reference Citation Analysis]
11 Liu Z, Netski DM, Mao Q, Laeyendecker O, Ticehurst JR, Wang XH, Thomas DL, Ray SC. Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol 2004;42:4223-9. [PMID: 15365015 DOI: 10.1128/JCM.42.9.4223-4229.2004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
12 Pan YF, Zheng Y, Qin T, Feng L, Zhang Q, Ping XG, Pan YT, Wang XP, Bai L, Li HH. Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion. Exp Ther Med. 2016;12:3476-3484. [PMID: 27882182 DOI: 10.3892/etm.2016.3792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Kim CY, Kim BR, Lee SS, Jeon DH, Lee CM, Kim WS, Cho HC, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5844. [PMID: 28079817 DOI: 10.1097/MD.0000000000005844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
14 Mustafa GM, Larry D, Petersen JR, Elferink CJ. Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. World J Hepatol 2015; 7(10): 1312-1324 [PMID: 26052377 DOI: 10.4254/wjh.v7.i10.1312] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
15 Zang GQ, Xi M, Feng ML, Ji Y, Yu YS, Tang ZH. Curative effects of interferon-α and HLA-DRB1 -DQA1 and -DQB1 alleles in chronic viral hepatitis B. World J Gastroenterol 2004; 10(14): 2116-2118 [PMID: 15237447 DOI: 10.3748/wjg.v10.i14.2116] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
16 Manzin A, Solforosi L, Petrelli E, Macarri G, Tosone G, Piazza M, Clementi M. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 1998;72:6271-6. [PMID: 9621104 DOI: 10.1128/JVI.72.7.6271-6276.1998] [Cited by in Crossref: 60] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
17 Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, Clute S, Wang C, Korman A, Sette A, Sidney J, Pardoll DM, Cox AL. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 2008;181:8215-25. [PMID: 19050238 DOI: 10.4049/jimmunol.181.12.8215] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 7.5] [Reference Citation Analysis]
18 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
19 Fujiwara A, Sakaguchi K, Fujioka S, Iwasaki Y, Senoh T, Nishimura M, Terao M, Shiratori Y. Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. J Gastroenterol 2008;43:484-91. [PMID: 18600393 DOI: 10.1007/s00535-008-2183-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
20 Sarin SK, Kumar M. Natural history of HCV infection. Hepatol Int 2012;6:684-95. [DOI: 10.1007/s12072-012-9355-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
21 Samis AJ. Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved? Crit Care Med 2008;36:1655-6. [PMID: 18448925 DOI: 10.1097/CCM.0b013e318170157b] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci. 1998;43:2573-2576. [PMID: 9881484 DOI: 10.1023/a:1026601904609] [Cited by in Crossref: 83] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
23 Bailey JR, Laskey S, Wasilewski LN, Munshaw S, Fanning LJ, Kenny-Walsh E, Ray SC. Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. J Virol 2012;86:12582-90. [PMID: 22973048 DOI: 10.1128/JVI.01440-12] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ray SC, Mao Q, Lanford RE, Bassett S, Laeyendecker O, Wang YM, Thomas DL. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol. 2000;74:3058-3066. [PMID: 10708420 DOI: 10.1128/JVI.74.7.3058-3066.2000] [Cited by in Crossref: 53] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
25 Abdo AA. Hepatitis C and poor quality of life: is it the virus or the patient? Saudi J Gastroenterol 2008;14:109-13. [PMID: 19568517 DOI: 10.4103/1319-3767.41727] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
26 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308. [PMID: 18666317 DOI: 10.3748/wjg.v14.i27.4300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J. Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service. Clinicoecon Outcomes Res 2017;9:163-72. [PMID: 28280374 DOI: 10.2147/CEOR.S117650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
28 Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136. [PMID: 10861275 DOI: 10.1136/gut.47.1.131] [Cited by in Crossref: 257] [Cited by in F6Publishing: 231] [Article Influence: 11.7] [Reference Citation Analysis]
29 Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines. 2011;10:659-672. [PMID: 21604986 DOI: 10.1586/erv.11.55] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
30 Salomon JA, Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. BMJ 2004;329:733-6. [PMID: 15388618 DOI: 10.1136/bmj.329.7468.733] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
31 Wu T, Konyn PG, Cattaneo AW, Saab S. New Face of Hepatitis C. Dig Dis Sci 2019;64:1782-8. [PMID: 30756208 DOI: 10.1007/s10620-019-05511-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
32 Xie W, Cao Y, Xu M, Wang J, Zhou C, Yang X, Geng X, Zhang W, Li N, Cheng J. Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. Sci Rep 2017;7:10289. [PMID: 28860489 DOI: 10.1038/s41598-017-11111-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Mindikoglu AL, Miller RR. Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol. 2009;7:128-34; quiz 124. [PMID: 19084480 DOI: 10.1016/j.cgh.2008.07.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
34 Butt AA, Yan P, Lo Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med. 2015;175:178-185. [PMID: 25485735 DOI: 10.1001/jamainternmed.2014.6502] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 8.1] [Reference Citation Analysis]
35 Mohsen AH; Trent HCV Study Group. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707-13. [PMID: 11302973 DOI: 10.1136/gut.48.5.707] [Cited by in Crossref: 69] [Cited by in F6Publishing: 80] [Article Influence: 3.3] [Reference Citation Analysis]
36 Deng Y, Palmeri ML, Rouze NC, Rosenzweig SJ, Abdelmalek MF, Nightingale KR. Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. Ultrasound Med Biol 2015;41:1948-57. [PMID: 25896024 DOI: 10.1016/j.ultrasmedbio.2015.02.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
37 Zheng Z, Sze CW, Keng CT, Al-Haddawi M, Liu M, Tan SY, Kwek HL, Her Z, Chan XY, Barnwal B, Loh E, Chang KTE, Tan TC, Tan YJ, Chen Q. Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One 2017;12:e0184127. [PMID: 28886065 DOI: 10.1371/journal.pone.0184127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
38 He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL, Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17:286-297. [PMID: 20227042 DOI: 10.1016/j.ccr.2009.12.048] [Cited by in Crossref: 291] [Cited by in F6Publishing: 286] [Article Influence: 24.3] [Reference Citation Analysis]
39 Yee LJ, Weiss HL, Langner RG, Herrera J, Kaslow RA, van Leeuwen DJ. Risk factors for acquisition of hepatitis C virus infection: a case series and potential implications for disease surveillance. BMC Infect Dis. 2001;1:8. [PMID: 11518542 DOI: 10.1186/1471-2334-1-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
40 Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, Pradat P, Thursz M; HENCORE collaboration. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574-9. [PMID: 12631672 DOI: 10.1136/gut.52.4.574] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
41 El-Ashry R, Malek HA, Ghayaty EA, El-Gendy AA, Darwish A, Al-Tonbary Y. Treatment for hepatitis C virus-induced portal hypertension in leukemic children. Med Oncol 2013;30:559. [PMID: 23553276 DOI: 10.1007/s12032-013-0559-y] [Reference Citation Analysis]
42 Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, O'Keane JC, Crowe J. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49:423-430. [PMID: 11511566 DOI: 10.1136/gut.49.3.423] [Cited by in Crossref: 107] [Cited by in F6Publishing: 103] [Article Influence: 5.1] [Reference Citation Analysis]
43 Netski DM, Wang XH, Mehta SH, Nelson K, Celentano D, Thongsawat S, Maneekarn N, Suriyanon V, Jittiwutikorn J, Thomas DL. Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users. J Clin Microbiol. 2004;42:1631-1636. [PMID: 15071017 DOI: 10.1128/JCM.42.4.1631-1636.2004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
44 Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18. [PMID: 18184025 DOI: 10.2165/00002512-200825010-00002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
45 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2007;3:469-76. [PMID: 24395487 DOI: 10.1007/s11908-007-1004-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
46 Argyropoulou MI, Astrakas L. MRI evaluation of tissue iron burden in patients with beta-thalassaemia major. Pediatr Radiol 2007;37:1191-200; quiz 1308-9. [PMID: 17710390 DOI: 10.1007/s00247-007-0567-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
47 Natarajan Y, El-Serag HB. Risk Factors for Hepatocellular Carcinoma: A Historical Perspective. Clin Liver Dis (Hoboken) 2021;18:1-13. [PMID: 34745580 DOI: 10.1002/cld.1042] [Reference Citation Analysis]
48 Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S206-14. [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5] [Cited by in Crossref: 347] [Cited by in F6Publishing: 196] [Article Influence: 28.9] [Reference Citation Analysis]
49 Shao Z, Lopez R, Shen B, Yang GS. Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy. World J Gastroenterol 2008; 14(27): 4370-4376 [PMID: 18666328 DOI: 10.3748/wjg.14.4370] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
50 Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer. 1997;76:968-974. [PMID: 9328161 DOI: 10.1038/bjc.1997.493] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 3.6] [Reference Citation Analysis]
51 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Aggarwal R, Singh SP, Amarapurkar D, Arora A, Chhabra M, Chetri K, Choudhuri G, Dixit VK, Duseja A, Jain AK, Kapoorz D, Kar P, Koshy A, Kumar A, Madan K, Misra SP, Prasad MV, Nagral A, Puri AS, Jeyamani R, Saigal S, Sarin SK, Shah S, Sharma PK, Sood A, Thareja S, Wadhawan M. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. J Clin Exp Hepatol 2014;4:106-16. [PMID: 25755548 DOI: 10.1016/j.jceh.2014.05.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
52 Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis. 2004;19:351-356. [PMID: 15554427 DOI: 10.1023/b: mebr.0000043981.89134.39] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Mennini FS, Marcellusi A, Robbins Scott S, Montilla S, Craxi A, Buti M, Gheorghe L, Ryder S, Kondili LA. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. Liver Int 2021;41:934-48. [PMID: 33529499 DOI: 10.1111/liv.14808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
54 Samis AJ. Delayed gastric emptying in critical illness: is enhanced enterogastric inhibition with cholecystokinin and peptide YY involved? Crit Care Med 2008;36:1655-6. [PMID: 18448925 DOI: 10.1097/CCM.0b013e318170157b] [Reference Citation Analysis]
55 Hézode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003;52:126-9. [PMID: 12477773 DOI: 10.1136/gut.52.1.126] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 4.6] [Reference Citation Analysis]
56 Takakusagi S, Takagi H, Kosone T, Sato K, Kakizaki S, Uraoka T. Prognosis of late elderly patients with chronic hepatitis C after achieving a sustained viral response by direct-acting antivirals. JGH Open 2021;5:122-7. [PMID: 33490621 DOI: 10.1002/jgh3.12459] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci. 1997;42:1681-1687. [PMID: 9286234 DOI: 10.1023/a:1018857314351] [Cited by in Crossref: 101] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
58 Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-389. [PMID: 17005764 DOI: 10.1136/gut.2006.099150] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 7.1] [Reference Citation Analysis]
59 Reid M, Price JC, Tien PC. Hepatitis C Virus Infection in the Older Patient. Infect Dis Clin North Am 2017;31:827-38. [PMID: 29079161 DOI: 10.1016/j.idc.2017.07.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
60 Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, Ghany MG, Alter HJ. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 2012;206:654-61. [PMID: 22740714 DOI: 10.1093/infdis/jis410] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
61 Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, Muss N, Sandhofer F, Vogel W. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut 1999;44:563-7. [PMID: 10075966 DOI: 10.1136/gut.44.4.563] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.1] [Reference Citation Analysis]
62 Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut. 2005;54:402-406. [PMID: 15710990 DOI: 10.1136/gut.2004.048009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
63 Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother. 2007;51:2016-2027. [PMID: 17420205 DOI: 10.1128/aac.01426-06] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
64 Kato T, Date T, Miyamoto M, Zhao Z, Mizokami M, Wakita T. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 2005;79:592-6. [PMID: 15596851 DOI: 10.1128/JVI.79.1.592-596.2005] [Cited by in Crossref: 101] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
65 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
66 Tillmann HL, Manns MP. Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups. Dig Dis Sci. 1996;41:27S-40S. [PMID: 9011473 DOI: 10.1007/bf02087874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
67 Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Pharmacoeconomics 2019;37:255-66. [PMID: 30378086 DOI: 10.1007/s40273-018-0733-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
68 Patil R, Cotler SJ, Banaad-Omiotek G, McNutt RA, Brown MD, Cotler S, Jensen DM. Physicians' preference values for hepatitis C health states and antiviral therapy: a survey. BMC Gastroenterol 2001;1:6. [PMID: 11513756 DOI: 10.1186/1471-230x-1-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
69 Tillmann HL, Chen DF, Trautwein C, Kliem V, Grundey A, Berning-Haag A, Böker K, Kubicka S, Pastucha L, Stangel W, Manns MP. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001;48:714-8. [PMID: 11302974 DOI: 10.1136/gut.48.5.714] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.0] [Reference Citation Analysis]
70 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol 2016;51:380-9. [DOI: 10.1007/s00535-015-1117-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
71 Mascheretti S, Hinrichsen H, Ross S, Buggisch P, Hampe J, Foelsch UR, Schreiber S. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol. 2004;136:328-333. [PMID: 15086398 DOI: 10.1111/j.1365-2249.2004.02444.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
72 Alscher DM, Bode JC. [Therapy of hepatitis C]. Med Klin (Munich) 1997;92:147-61. [PMID: 9173207 DOI: 10.1007/BF03043273] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
73 Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract 2013;19:292-300. [PMID: 23186968 DOI: 10.4158/EP12195.RA] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
74 Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, Peck-Radosavljevic M. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014-20. [PMID: 15951552 DOI: 10.1136/gut.2004.057893] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
75 Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, Busch MP, Murphy EL. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol. 2008;167:743-750. [PMID: 18203734 DOI: 10.1093/aje/kwm370] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 6.7] [Reference Citation Analysis]
76 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 9.5] [Reference Citation Analysis]
77 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: A reasonable strategy? Ann Surg. 2003;238:508-18; discussion 518-9. [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44] [Cited by in Crossref: 66] [Cited by in F6Publishing: 131] [Article Influence: 3.5] [Reference Citation Analysis]
78 Jacobson JM, Feinman L, Liebes L, Ostrow N, Koslowski V, Tobia A, Cabana BE, Lee D, Spritzler J, Prince AM. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001;45:517-24. [PMID: 11158749 DOI: 10.1128/AAC.45.2.517-524.2001] [Cited by in Crossref: 92] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
79 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14(27): 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300] [Cited by in CrossRef: 408] [Cited by in F6Publishing: 377] [Article Influence: 29.1] [Reference Citation Analysis]
80 Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999;44:624-630. [PMID: 10080160 DOI: 10.1023/a:1026630129025] [Cited by in Crossref: 98] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
81 Lee MH, Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Yang JM, Han KH, Cho SW. Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. Dig Dis Sci. 2010;55:3552-3560. [PMID: 20428950 DOI: 10.1007/s10620-010-1219-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
82 Senturk H, Uzunalimoglu O, Batur Y, Simsek I, Mert A, Ozbay G, Cetinkaya H, Ersoz G, Tabak F, Akbaylar H, Akdogan M, Dokmeci A, Sonsuz A, Ozenirler S, Erden E, Tozum N. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis. Dig Dis Sci 1997;42:1438-44. [PMID: 9246043 DOI: 10.1023/a:1018854424403] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
83 Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis 2013;13:190. [PMID: 23621902 DOI: 10.1186/1471-2334-13-190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
84 Falade-Nwulia O, Thio CL. Liver disease, HIV and aging. Sex Health 2011;8:512-20. [PMID: 22127037 DOI: 10.1071/SH10163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
85 He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL, Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010;17:286-97. [PMID: 20227042 DOI: 10.1016/j.ccr.2009.12.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Yang J, Nugroho AS, Yamauchi K, Yoshioka K, Zheng J, Wang K, Kato K, Kuroyanagi S, Iwata A. Efficacy of interferon treatment for chronic hepatitis C predicted by feature subset selection and support vector machine. J Med Syst 2007;31:117-23. [PMID: 17489504 DOI: 10.1007/s10916-006-9046-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
87 Newton OE, Oghene OA, Okonko IO. Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria. Afr Health Sci 2015;15:728-36. [PMID: 26957959 DOI: 10.4314/ahs.v15i3.5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
88 Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42:104-112. [PMID: 15962289 DOI: 10.1002/hep.20749] [Cited by in Crossref: 154] [Cited by in F6Publishing: 167] [Article Influence: 9.1] [Reference Citation Analysis]
89 Yalamanchili K, Saadeh S, Lepe R, Davis GL. The prevalence of hepatitis C virus infection in Texas: implications for future health care. Proc (Bayl Univ Med Cent) 2005;18:3-6. [PMID: 16200141 DOI: 10.1080/08998280.2005.11928024] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
90 Vasudevan S, Kavimandan A, Kalra N, Nayak B, Thakur B, Das P, Gupta SD, Panda SK, Acharya SK; Shalimar. Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north India. Indian J Med Res 2016;143:331-40. [PMID: 27241647 DOI: 10.4103/0971-5916.182624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
91 Eyster ME, Kong L, Li M, Schreibman IR. Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort. Am J Hematol 2016;91:E335-40. [PMID: 27214557 DOI: 10.1002/ajh.24427] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
92 Queiroz DM, Rocha AM, Rocha GA, Cinque SM, Oliveira AG, Godoy A, Tanno H. Association between Helicobacter pylori infection and cirrhosis in patients with chronic hepatitis C virus. Dig Dis Sci 2006;51:370-3. [PMID: 16534683 DOI: 10.1007/s10620-006-3150-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
93 Chitapanarux T, Phornphutkul K. Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. J Clin Transl Hepatol 2015;3:182-8. [PMID: 26623264 DOI: 10.14218/JCTH.2015.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.4] [Reference Citation Analysis]
94 Murata M, Yoshida K, Yamaguchi T, Matsuzaki K. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma. World J Gastroenterol 2014; 20(41): 15018-15027 [PMID: 25386050 DOI: 10.3748/wjg.v20.i41.15018] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
95 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
96 Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011;53:1100-1108. [PMID: 21480316 DOI: 10.1002/hep.24169] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
97 Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis 2004;19:351-6. [PMID: 15554427 DOI: 10.1023/b:mebr.0000043981.89134.39] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
98 Ku KS, Chodavarapu RK, Martin R, Miller MD, Mo H, Svarovskaia ES. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. J Clin Microbiol 2016;54:1835-41. [PMID: 27147726 DOI: 10.1128/JCM.00238-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
100 Walsh K, Alexander GJ. Update on chronic viral hepatitis. Postgrad Med J 2001;77:498-505. [PMID: 11470928 DOI: 10.1136/pmj.77.910.498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
101 Badiani RG, Becker V, Perez RM, Matos CA, Lemos LB, Lanzoni VP, Andrade LEC, Dellavance A, Silva AEB, Ferraz MLG. Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? World J Gastroenterol 2010; 16(29): 3704-3708 [PMID: 20677344 DOI: 10.3748/wjg.v16.i29.3704] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
102 Ito W, Toyama M, Okamoto M, Ikeda M, Watashi K, Wakita T, Hashimoto Y, Baba M. Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative. Antivir Chem Chemother 2015;24:148-54. [PMID: 27503576 DOI: 10.1177/2040206616663956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Chen JC, Chang ML, Lin JN, Lai HS, Chen CC, Chen WJ, Hung WT. Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area. World J Gastroenterol 2005; 11(34): 5289-5294 [PMID: 16149134 DOI: 10.3748/wjg.v11.i34.5289] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
104 Piche T, Gelsi E, Schneider SM, Hébuterne X, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Hastier P, Montoya ML. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut. 2002;51:434-439. [PMID: 12171970 DOI: 10.1136/gut.51.3.434] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.4] [Reference Citation Analysis]
105 Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131-136. [PMID: 10861275 DOI: 10.1136/gut.47.1.131.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Tiwari AK, Laird-Fick HS, Wali RK, Roy HK. Surveillance for gastrointestinal malignancies. World J Gastroenterol 2012; 18(33): 4507-4516 [PMID: 22969223 DOI: 10.3748/wjg.v18.i33.4507] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
107 Yoon YH, Yi HY, Thomson PC. Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004. Alcohol Clin Exp Res 2011;35:240-9. [PMID: 21121934 DOI: 10.1111/j.1530-0277.2010.01340.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
108 Anand BS, Velez M. Assessment of correlation between serum titers of hepatitis c virus and severity of liver disease. World J Gastroenterol 2004; 10(16): 2409-2411 [PMID: 15285030 DOI: 10.3748/wjg.v10.i16.2409] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
109 Plosker GL, Keating GM. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. Drugs 2004;64:2823-43. [PMID: 15563253 DOI: 10.2165/00003495-200464240-00009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
110 Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, Perrone MP, Girelli G, Del Porto P, Piccolella E, Mondelli MU, Amoroso P, Cortese R, Nicosia A, Vitelli A, Folgori A. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673-1681. [PMID: 15479691 DOI: 10.1136/gut.2003.037788] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 4.0] [Reference Citation Analysis]
111 Wünschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000;74:10055-62. [PMID: 11024134 DOI: 10.1128/jvi.74.21.10055-10062.2000] [Cited by in Crossref: 161] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
112 Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010;2010:548280. [PMID: 20625493 DOI: 10.1155/2010/548280] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
113 Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 1998;78:781-7. [PMID: 9743301 DOI: 10.1038/bjc.1998.579] [Cited by in Crossref: 60] [Cited by in F6Publishing: 41] [Article Influence: 2.5] [Reference Citation Analysis]
114 Li Y, Zhang T, Douglas SD, Lai JP, Xiao WD, Pleasure DE, Ho WZ. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol. 2003;163:1167-1175. [PMID: 12937158 DOI: 10.1016/s0002-9440(10)63476-1] [Cited by in Crossref: 52] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
115 Mathew A, Peiffer LP, Rhoades K, McGarrity TJ. Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin. Health Qual Life Outcomes 2006;4:30. [PMID: 16696859 DOI: 10.1186/1477-7525-4-30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
116 Vidal-Castiñeira JR, López-Vázquez A, Díaz-Peña R, Alonso-Arias R, Martínez-Borra J, Pérez R, Fernández-Suárez J, Melón S, Prieto J, Rodrigo L, López-Larrea C. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 2010;84:475-81. [PMID: 19846535 DOI: 10.1128/JVI.01285-09] [Cited by in Crossref: 60] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
117 Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics. 2006;24:661-672. [PMID: 16802842 DOI: 10.2165/00019053-200624070-00005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
118 Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: A frequently underestimated combination. World J Gastroenterol 2009; 15(28): 3462-3471 [PMID: 19630099 DOI: 10.3748/wjg.15.3462] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
119 Saab S, Rheem J, Sundaram V. Hepatitis C Infection in the Elderly. Dig Dis Sci. 2015;60:3170-3180. [PMID: 26008618 DOI: 10.1007/s10620-015-3717-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
120 Kim DD, Hutton DW, Raouf AA, Salama M, Hablas A, Seifeldin IA, Soliman AS. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health. 2015;10:296-317. [PMID: 25469976 DOI: 10.1080/17441692.2014.984742] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
121 Keating S, Coughlan S, Connell J, Sweeney B, Keenan E. Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area. Ir J Med Sci 2005;174:37-41. [PMID: 15868888 DOI: 10.1007/BF03168517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
122 Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG. Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Int J Med Sci 2004;1:92-100. [PMID: 15912201 DOI: 10.7150/ijms.1.92] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
123 Papatheodoridis GV, Papakonstantinou E, Andrioti E, Cholongitas E, Petraki K, Kontopoulou I, Hadziyannis SJ. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut. 2003;52:404-409. [PMID: 12584224 DOI: 10.1136/gut.52.3.404] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 4.0] [Reference Citation Analysis]
124 Montes-Cano M, García-Lozano J, Aguilar-Reina J, Romero-Gómez M, Barroso N, Núñez-Roldán A, González-Escribano M. CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population. World J Gastroenterol 2007; 13(15): 2187-2192 [PMID: 17465499 DOI: 10.3748/wjg.v13.i15.2187] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
125 Giannini EG, Basso M, Savarino V, Picciotto A. Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig Dis Sci 2010;55:3193-9. [PMID: 20848200 DOI: 10.1007/s10620-010-1408-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
126 Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998;72:3827-36. [PMID: 9557666 DOI: 10.1128/JVI.72.5.3827-3836.1998] [Cited by in Crossref: 280] [Cited by in F6Publishing: 105] [Article Influence: 11.7] [Reference Citation Analysis]
127 Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, Goldin R, Hill AV, Thomas HC, Thursz MR. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 2003;55:362-369. [PMID: 12942209 DOI: 10.1007/s00251-003-0594-5] [Cited by in Crossref: 116] [Cited by in F6Publishing: 109] [Article Influence: 6.1] [Reference Citation Analysis]
128 Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99. [PMID: 19207971 DOI: 10.1111/j.1478-3231.2008.01927.x] [Cited by in Crossref: 161] [Cited by in F6Publishing: 151] [Article Influence: 12.4] [Reference Citation Analysis]
129 Carty PG, McCarthy M, O'Neill SM, De Gascun CF, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy. Rev Med Virol 2021;:e2320. [PMID: 34957630 DOI: 10.1002/rmv.2320] [Reference Citation Analysis]
130 Choi J, Corder NL, Koduru B, Wang Y. Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med 2014;72:267-84. [PMID: 24816297 DOI: 10.1016/j.freeradbiomed.2014.04.020] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
131 Cheikh A, Ajaja MR, Rhazali H, Bouatia M, Benomar A, Slaoui A, Cherrah Y, Abouqal R, El Hassani A, Cheikhaoui Y. Contribution of fibrin glue in the surgery of cyanogenic and non-cyanogenic congenital cardiopathies: retrospective cohort study. BMC Cardiovasc Disord 2019;19:117. [PMID: 31096916 DOI: 10.1186/s12872-019-1102-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Liu JY, Sheng YJ, Hu HD, Zhong Q, Wang J, Tong SW, Zhou Z, Zhang DZ, Hu P, Ren H. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J. 2012;9:186. [PMID: 22950520 DOI: 10.1186/1743-422x-9-186] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
133 Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, Sidney J, Sette A, Pardoll D, Thomas DL, Ray SC. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med. 2005;201:1741-1752. [PMID: 15939790 DOI: 10.1084/jem.20050121] [Cited by in Crossref: 225] [Cited by in F6Publishing: 216] [Article Influence: 13.2] [Reference Citation Analysis]
134 Cooper CL, Mills EJ. Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduct J 2006;3:31. [PMID: 17096852 DOI: 10.1186/1477-7517-3-31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
135 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. J Med Virol 2019;91:1837-44. [PMID: 31254403 DOI: 10.1002/jmv.25533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
136 Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia MA, Wang P, Otto MJ, Furman PA. The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008;52:458-64. [PMID: 17999967 DOI: 10.1128/AAC.01184-07] [Cited by in Crossref: 90] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
137 Chen HM, Wan H, Yu M, Tian XL, Wei L, Xu XY. Relationship between HCV RNA quantities and HCV genotypes and the outcome of patients with posttransfusion hepatitis C virus infection. Shijie Huaren Xiaohua Zazhi 2004; 12(6): 1299-1302 [DOI: 10.11569/wcjd.v12.i6.1299] [Reference Citation Analysis]
138 Manzin A, Solforosi L, Debiaggi M, Zara F, Tanzi E, Romanò L, Zanetti AR, Clementi M. Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J Virol. 2000;74:4327-4334. [PMID: 10756048 DOI: 10.1128/jvi.74.9.4327-4334.2000] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
139 Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67:411-431. [PMID: 28683174 DOI: 10.3322/caac.21403] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
140 He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;21:159-68. [PMID: 21187858 DOI: 10.1038/cr.2010.183] [Cited by in Crossref: 648] [Cited by in F6Publishing: 642] [Article Influence: 54.0] [Reference Citation Analysis]
141 Lee MH, Yang HI, Yuan Y, L’Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014; 20(28): 9270-9280 [PMID: 25071320 DOI: 10.3748/wjg.v20.i28.9270] [Cited by in F6Publishing: 55] [Reference Citation Analysis]
142 Harris HE, Ramsay ME, Andrews N, Eldridge KP; HCV National Register Steering Group. Hepatitis C virus. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:450-3. [PMID: 11859045 DOI: 10.1136/bmj.324.7335.450] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 3.5] [Reference Citation Analysis]
143 Burke KP, Cox AL. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res. 2010;47:216-227. [PMID: 20066508 DOI: 10.1007/s12026-009-8152-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
144 Jafferbhoy H, Gashau W, Dillon J. Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res 2010;2:87-96. [PMID: 21935317 DOI: 10.2147/ceor.s7283] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
145 Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol 2015; 21(38): 10760-10775 [PMID: 26478668 DOI: 10.3748/wjg.v21.i38.10760] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
146 Castéra L, Hézode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003;52:288-92. [PMID: 12524415 DOI: 10.1136/gut.52.2.288] [Cited by in Crossref: 217] [Cited by in F6Publishing: 200] [Article Influence: 11.4] [Reference Citation Analysis]
147 Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterol 2020;20:215. [PMID: 32646378 DOI: 10.1186/s12876-020-01365-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
148 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
149 Bobeck DR, Schinazi RF, Coats SJ. Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther 2010;15:935-50. [PMID: 21041908 DOI: 10.3851/IMP1667] [Cited by in Crossref: 48] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
150 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
151 Villani R, Cavallone F, Romano AD, Bellanti F, Serviddio G. Two-Dimensional Shear Wave Elastography versus Transient Elastography: A Non-Invasive Comparison for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C. Diagnostics (Basel) 2020;10:E313. [PMID: 32429410 DOI: 10.3390/diagnostics10050313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507-556. [PMID: 11827565 DOI: 10.2165/00003495-200262030-00009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
153 Briggs A, Shiell A. Interferon-alpha in hepatitis C. Dosage, costs and benefits. Pharmacoeconomics 1996;10:205-9. [PMID: 10163569 DOI: 10.2165/00019053-199610030-00002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, Kirk GD, Segev DL, Nelson KE, Marks M, Heller T, Golub ET. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202:845-852. [PMID: 20701536 DOI: 10.1086/655808] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
155 Coats SJ, Garnier-Amblard EC, Amblard F, Ehteshami M, Amiralaei S, Zhang H, Zhou L, Boucle SR, Lu X, Bondada L, Shelton JR, Li H, Liu P, Li C, Cho JH, Chavre SN, Zhou S, Mathew J, Schinazi RF. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res 2014;102:119-47. [PMID: 24275341 DOI: 10.1016/j.antiviral.2013.11.008] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 6.3] [Reference Citation Analysis]
156 Wei S, Suryani Y, Gowda GA, Skill N, Maluccio M, Raftery D. Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling. Metabolites. 2012;2:701-716. [PMID: 24957758 DOI: 10.3390/metabo2040701] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
157 Jobarteh M, Malfroy M, Peterson I, Jeng A, Sarge-Njie R, Alabi A, Peterson K, Cotten M, Hall A, Rowland-Jones S. Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J. 2010;7:230. [PMID: 20843322 DOI: 10.1186/1743-422x-7-230] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
158 Walsh KM, Leen E, MacSween RN, Morris AJ. Hepatic blood flow changes in chronic hepatitis C measured by duplex Doppler color sonography: relationship to histological features. Dig Dis Sci. 1998;43:2584-2590. [PMID: 9881486 DOI: 10.1023/a:1026626505517] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
159 Minuk GY, Uhanova J, Kaita KD. The prevalence of intrinsic host risk factors associated with progressive disease in patients with chronic hepatitis C viral infections. Can J Public Health 2000;91:171-5. [PMID: 10927842 [PMID: 10927842 DOI: 10.1007/bf03404265] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
160 Pei R, Zhang X, Xu S, Meng Z, Roggendorf M, Lu M, Chen X. Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway. Virol Sin 2012;27:278-85. [PMID: 23001481 DOI: 10.1007/s12250-012-3257-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
161 Minuk GY, Cohen AJ, Assy N, Moser M. Viral hepatitis and the surgeon. HPB (Oxford) 2005;7:56-64. [PMID: 18333162 DOI: 10.1080/13651820410016633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
162 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2134] [Cited by in F6Publishing: 1938] [Article Influence: 164.2] [Reference Citation Analysis]
163 Chen S, Wang YM. Genetic evolution of structural region of hepatitis C virus in primary infection. World J Gastroenterol 2002; 8(4): 686-693 [PMID: 12174379 DOI: 10.3748/wjg.v8.i4.686] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
164 Totani H, Kusumoto S, Tanaka Y, Suzuki N, Hagiwara S, Kinoshita S, Iio E, Ito A, Ri M, Ishida T, Komatsu H, Iida S. The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy. Int J Hematol 2016;104:384-91. [PMID: 27255233 DOI: 10.1007/s12185-016-2033-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
165 Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM; US Hemophilia Treatment Center Network. Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood 2016;127:3073-81. [PMID: 26983851 DOI: 10.1182/blood-2015-10-675140] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
166 Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol 2015; 21(24): 7412-7426 [PMID: 26139987 DOI: 10.3748/wjg.v21.i24.7412] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
167 Zhao X, Tang ZY, Klumpp B, Wolff-Vorbeck G, Barth H, Levy S, von Weizsäcker F, Blum HE, Baumert TF. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest. 2002;109:221-232. [PMID: 11805134 DOI: 10.1172/jci13011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 35] [Article Influence: 0.3] [Reference Citation Analysis]
168 Sbarigia U, Denee TR, Turner NG, Wan GJ, Morrison A, Kaufman AS, Rice G, Dusheiko GM. Conceptual framework for outcomes research studies of hepatitis C: an analytical review. Infect Drug Resist 2016;9:101-17. [PMID: 27313473 DOI: 10.2147/IDR.S99329] [Reference Citation Analysis]
169 Ramsey SE, Engler PA, Stein MD, Brown RA, Cioe P, Kahler CW, Promrat K, Rose J, Anthony J, Solomon DA. Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. J Addict Res Ther 2011;2:2-10. [PMID: 21743837 DOI: 10.4172/2155-6105.1000109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
170 Sookoian S, Castaño G, Frider B, Cello J, Campos R, Flichman D. Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity. Dig Dis Sci 2001;46:1067-71. [PMID: 11341650 DOI: 10.1023/a:1010718213584] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
171 Saito H, Tada S, Ebinuma H, Ishii H, Kashiwazaki K, Takahashi M, Tsukada N, Nishida J, Tanaka S, Shiozaki H, Hibi T. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006;44:3562-8. [PMID: 17021083 DOI: 10.1128/JCM.00079-06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
172 Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010;84:5067-77. [PMID: 20200239 DOI: 10.1128/JVI.02265-09] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
173 Sakata K, Hara M, Terada T, Watanabe N, Takaya D, Yaguchi S, Matsumoto T, Matsuura T, Shirouzu M, Yokoyama S, Yamaguchi T, Miyazawa K, Aizaki H, Suzuki T, Wakita T, Imoto M, Kojima S. HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-β type I receptor. Sci Rep 2013;3:3243. [PMID: 24263861 DOI: 10.1038/srep03243] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
174 Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997;35:3274-7. [PMID: 9399533 DOI: 10.1128/jcm.35.12.3274-3277.1997] [Cited by in Crossref: 151] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
175 Wellnitz S, Klumpp B, Barth H, Ito S, Depla E, Dubuisson J, Blum HE, Baumert TF. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol. 2002;76:1181-1193. [PMID: 11773394 DOI: 10.1128/JVI.76.3.1181-1193.2002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
176 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
177 Tai CL, Pan WC, Liaw SH, Yang UC, Hwang LH, Chen DS. Structure-based mutational analysis of the hepatitis C virus NS3 helicase. J Virol 2001;75:8289-97. [PMID: 11483774 DOI: 10.1128/jvi.75.17.8289-8297.2001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
178 Brown RJ, Hudson N, Wilson G, Rehman SU, Jabbari S, Hu K, Tarr AW, Borrow P, Joyce M, Lewis J. Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. J Virol. 2012;86:11956-11966. [PMID: 22855498 DOI: 10.1128/jvi.01079-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
179 Tian ZF, Shen H, Fu XH, Chen YC, Blum HE, Baumert TF, Zhao XP. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. World J Gastroenterol 2009; 15(2): 240-244 [PMID: 19132776 DOI: 10.3748/wjg.15.240] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
180 Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28:6367-6373. [PMID: 20619382 DOI: 10.1016/j.vaccine.2010.06.084] [Cited by in Crossref: 152] [Cited by in F6Publishing: 142] [Article Influence: 12.7] [Reference Citation Analysis]
181 Shchanitcyna SE, Burnevich EZ, Nikulkina EN, Filatova AL, Мoiseev SV, Мukhin NA. Risk factors of unfavorable prognosis of chronic hepatitis C. Ter Arkh 2019;91:59-66. [PMID: 31094173 DOI: 10.26442/00403660.2019.02.000082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]